One example of on-target, off-tissue toxicity was reported in a Phase I clinical trial of renal cell carcinoma patients treated with autologous CAR T-cells engineered to recognize an epitope within the carbonic anhydrase IX (CAIX) tumor-associated protein[113]. This evidence concerns the gene CA9 and hereditary clear cell renal cell carcinoma.